## **Core Concept**
The question tests knowledge of anaesthetic agents in the context of renal failure. In patients with renal failure, the choice of anaesthetic agent is crucial because many agents or their metabolites are excreted by the kidneys. The ideal agent should have minimal renal excretion or be metabolized in a way that does not rely on renal function.

## **Why the Correct Answer is Right**
Propofol (**Option C**) is often considered a safe choice for patients with renal failure. This is because propofol is primarily metabolized by the liver into inactive metabolites, which are then excreted. Unlike some other anaesthetic agents, propofol does not rely on renal excretion to a significant extent, making it suitable for patients with compromised renal function. Its pharmacokinetic profile allows for rapid recovery, which is beneficial in patients with renal failure who may have altered drug metabolism.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Etomidate is metabolized by the liver but can have effects on adrenal function. While it can be used in patients with renal failure, it's not specifically chosen for this reason over others.
- **Option B:** Midazolam, a benzodiazepine, is metabolized by the liver but its active metabolites can accumulate in renal failure, potentially prolonging sedation.
- **Option D:** Thiopentone is metabolized by the liver but can have a prolonged effect in patients with renal failure due to its redistribution and potential for accumulation of its metabolites.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that propofol is often favoured in patients with renal failure due to its pharmacokinetic profile that does not heavily rely on renal excretion. However, careful consideration of fluid status and haemodynamic stability is still crucial when administering anaesthesia to patients with renal failure.

## **Correct Answer:** C. Propofol.